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Abstract 
Cognitive deficits in schizophrenia are thought to be caused, in part, by disrupted prefrontal 
cholinergic and glutamatergic transmission. Activation of the α7 nicotinic acetylcholine receptor 
(α7nAChR) has been shown to increase prefrontal glutamate as well as rescue failing 
performance in cognitive tasks in rodents and primates. Intra-accumbens stimulation with 
NMDA dose-dependently increases prefrontal acetylcholine, which in turn increases prefrontal 
glutamate via α7nAChR activity. Using NMDA stimulation as an assay to examine the 
potentiation of glutamate release as a function of the amount of acetylcholine released in the 
PFC, the potentiation profiles of two α7nAChR positive allosteric modulators (PAMs), AVL-
3288 and PNU-120596, were assessed at varying levels of PAM and stimulation. Second-by-
second measurements with a glutamate-sensitive microelectrode in the PFC in awake rats reveal 
that only an appropriate combination of the dose of NMDA and dose of PAM consistently 
potentiates prefrontal glutamate release. However, at other concentrations of NMDA and PAM, 
the effect on mesolimbic stimulation varied greatly from significant potentiation to a reduction of 
glutamate release. Furthermore, the potentiation profile for the type I and type II PAMs differed 
significantly, possibly due to differences in receptor desensitization in the presence of these two 
drugs. Overall, these results demonstrate the importance of dose of α7nAChR PAMs in 
modulating neurotransmitter systems, and PAMs as a potential therapeutic in treating cognitive 
deficits of schizophrenia as effects were dependent on activity of the orthosteric ligand. 
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Introduction 
Schizophrenia is a chronic brain disorder disrupting thought, perception, and behavior. 
Schizophrenia is prevalent in roughly 1% of the population and has an economic burden 
exceeding $62 billion/year in the United States alone (Perala et al., 2007; Wu et al., 2005). 
Diagnosis typically occurs after the first psychotic episode, occurring in late adolescence to early 
adulthood in men and throughout early adulthood in women, although prodromal symptoms are 
often present before this episode (Faraone et al. 1994; White et al., 2006). While the age of the 
first psychotic episode varies between men and women, both are affected in equal numbers (Saha 
et al., 2005). Not only does schizophrenia affect equal numbers across sex, culture, and 
socioeconomic status, the symptoms of the disorder also appear to be conserved across these 
demographic factors as well (Saha et al., 2006; Karagianis et al., 2009).This similar presentation 
is not to say that schizophrenia is a homogeneous disorder, but rather that schizophrenia is a 
worldwide problem with significant psychosocial and economic impact. 
Schizophrenia is a heterogeneous disorder composed of symptoms from three symptom 
clusters: positive, negative, and cognitive symptoms. Positive symptoms include features of the 
disease that are present in patients that are not present in the general population. These symptoms 
include hallucinations, delusions, and disorganized thought and speech (American Psychiatric 
Association, 2013). Similarly, negative symptoms of schizophrenia include features that are 
absent in schizophrenia but present in the general population, including flattened affect, 
avolition, and anhedonia (American Psychiatric Association, 2013). Lastly, schizophrenia 
presents with cognitive deficits, or deficits in thought processes (Kerns et al., 2008). Aspects of 
executive functioning are impaired in schizophrenia, particularly in working memory, cognitive 
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flexibility, and attentional processing. Current antipsychotic medications are effective at 
addressing some, but not all, of the symptoms associated with schizophrenia.  
The first antipsychotic, chlorpromazine (trade name Thorazine), was originally developed 
as an anesthetic agent, yet successfully reduced many of the positive symptoms associated with 
schizophrenia (Ban, 2007). The success of chlorpromazine led to the development of similar 
drugs, known as first generation, or typical, antipsychotics. This class of antipsychotic 
medication exerts its antipsychotic effects as D2 antagonists (Kapur & Mamo, 2003). 
Additionally, these medications have activity on the cholinergic, histaminergic, and adrenergic 
systems, which caused a variety of side effects such as dry mouth, weight gain, and sedation. The 
most debilitating and possibly permanent side effects of typical antipsychotics are 
extrapyramidal side effects, which are caused by high D2 occupancy leading to a dopamine 
hypofunction in extrapyramidal pathways, similar to what is seen in Parkinson’s disease 
(Tuppurainen et al., 2010). Extrapyramidal side effects involve movement difficulties, including 
dystonia, tremors, akathisia, bradykinesia, and tardive dyskinesia. To reduce these side effects, 
second generation, or atypical, antipsychotics were developed that bind more transiently to the 
D2 receptor, allowing for more endogenous dopamine binding, and additionally serve as 5-HT2A 
antagonists producing antipsychotic effects (Seeman 2002). While atypical antipsychotics had a 
smaller side effect profile than typical antipsychotics, they were no more efficacious than some 
typical antipsychotics in their antipsychotic properties (Lieberman & Stroup 2011). Both classes 
of drugs are capable at reducing many of the positive and negative symptoms; however, neither 
sufficiently address cognitive symptoms and subsequently, cognitive symptoms remain untreated 
(Keefe, 2007a; 2007b).  
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Cognitive deficits of schizophrenia result in a poorer quality of life and are more 
debilitating to daily function than positive or negative symptoms (Swartz et al., 2007). Cognitive 
function is often the best predictor of long-term functional outcome in the treatment of 
schizophrenia (Green et al., 2000). Presumably, improving cognitive functioning in patients with 
schizophrenia will improve their treatment outcome and quality of life. Poor cognitive function 
may predict a poor prognosis because poor cognitive function is a barrier to employment and a 
risk factor for the discontinuation of treatment (Rosenheck et al., 2006; Robinson et al. 2002). In 
addition to a personal decline in quality of life, cognitive symptoms contribute to the social and 
economic burden of the disease; therefore, it is imperative to improve treatments aimed at 
ameliorating the cognitive deficits associated with schizophrenia. 
Many aspects of cognition are mediated via a distributed neural network comprised of 
cortical and subcortical structures. The prefrontal cortex (PFC), serving as a source of top-down 
control, is important in all aspects of higher-order cognition (Miller, 2000). The PFC plays 
important roles in goal-directed behavior, personality expression, error detection, and problem 
solving. Disruptions in prefrontal activity can lead to deficits in tasks designed to measure 
working memory, cognitive flexibility and attentional processing (Demakis, 2004). It should 
serve as no surprise that the prefrontal cortices of individuals with schizophrenia appear 
disrupted. The brains of patients with schizophrenia display hypofrontality, or decreased 
prefrontal activity, both at rest and during cognitive task performance (Berman et al., 1992). 
Individuals with schizophrenia also display deficits in tasks dependent on prefrontal activity, 
such as the Stroop task and Wisconsin card sorting test (Barch et al., 2004; Haut et al., 1996). In 
longitudinal studies, patients who are later diagnosed with schizophrenia have reduced prefrontal 
gray matter at the time of their first episode (Hirayasu et al., 2001; Molina et al., 2006). Thus, 
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prefrontal irregularities may be involved in the cognitive deficits present in schizophrenia as 
similar deficits are seen in both patients with schizophrenia as well as frontal lobe damage. 
Glutamate, the primary excitatory neurotransmitter in the CNS, is important for cognitive 
performance. Disrupted prefrontal glutamate transmission can lead to impaired performance in a 
variety of cognitive tasks, including tasks designed to measure working memory, cognitive 
flexibility, attentional processing, and sensory gating (Umbrecht et al. 2000). Similarly, 
enhancing glutamate transmission in the PFC may lead to increased cognitive performance. 
Genetic risk factors in schizophrenia, including altered expression of catechol-o-methyl 
transferase (COMT), dysbindin, neuregulin, disrupted in schizophrenia 1 (DISC1), regulator of 
G-protein signaling 4 (RGS4), metabotropic glutamate receptor-3 (GRM3), and G72, have been 
linked to disruptions in glutamate transmission (Harrison & Weinberger 2004). Additionally, 
transcript expression for vesicular glutamate transporter-1 (VGLUT1) is down-regulated in the 
prefrontal cortex of individuals with schizophrenia, likely negatively affecting glutamate 
transport and release (Eastwood & Harrison, 2004). Furthermore, the activity of excitatory amino 
acid transporters (EAATs) appears disrupted in schizophrenia. Glial EAATs (i.e. EAAT1 and 
EAAT2) are down-regulated, possibly leading to an increase in autoreceptor activation and 
compensatory up-regulation of neuronal EAATs (i.e. EAAT3), which together, lead to a decrease 
in synaptic glutamate and increase in extrasynaptic glutamate (Bauer et al. 2008). Accordingly, 
group II metabotropic glutamate receptor expression is increased in the prefrontal cortex in 
schizophrenia (Gupta et al. 2005). Altered expression of the NMDA receptor, a glutamate 
receptor important in learning and memory, has been noted in the dorsolateral PFC and anterior 
cingulate cortex in schizophrenic brains (Kristiansen et al., 2006). Antagonism of the NMDAR is 
capable of producing psychotic symptoms in non-diseased individuals and exacerbates psychotic 
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symptoms in schizophrenic individuals (Krystal et al. 1994; Lahti et al., 1995). Additionally, 
NMDA blockade produces cognitive deficits in humans and animals and is frequently used as an 
animal model for cognitive deficits in schizophrenia (Krystal et al., 1994; Blot et al., 2013). 
Taken together, disruptions of glutamate transmission in the PFC may lead to glutamatergic 
hypofunction and underlie cognitive deficits seen in the disorder; therefore, methods of 
enhancing prefrontal glutamate may have pro-cognitive effects and serve to ameliorate the 
cognitive deficits seen in schizophrenia.  
Prefrontal glutamate can be modulated bi-directionally via the α7 nicotinic acetylcholine 
receptor (α7nAChR; Konradsson-Geuken et al., 2010). The α7nAChR is a homopentameric 
heteroreceptor, located pre- and postsynaptically, that gates cations (i.e. calcium, sodium, 
potassium)(Dajas-Bailador & Wonnacott, 2004). Calcium ion influx through the α7nAChR 
initiates a signal cascade known as the extracellular signal-regulated kinase 1/2 (ERK1/2) 
pathway (also known as the mitogen-activated protein kinase (MAPK) pathway), which is a 
transduction mechanism that has implications for learning and memory (Gubbins et al., 2010). 
Thus, presynaptic α7nAChR activity enhances neurotransmitter release both by causing 
depolarization at the axon terminal as well as affecting gene expression. In this manner, 
acetylcholine and other direct agonists of the α7nAChR are able to enhance glutamate 
transmission, while antagonism of the α7nAChR decreases glutamate transmission (Bortz et al., 
2013; Wu et al., 2010). Similarly, drugs that increase α7nAChR activity in the PFC have pro-
cognitive effects in rodents and result in an increased performance in a variety of cognitive tasks, 
while drugs that reduce α7nAChR activity can produce cognitive deficits (Redrobe et al., 2009; 
Thomsen et al., 2009; Castner et al., 2011; Alexander et al., 2012). Therefore, increasing 
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α7nAChR activity may serve as a target for cognitive-enhancing therapeutics in schizophrenia by 
enhancing several neurotransmitter systems, including glutamate. 
In schizophrenia, α7nAChR activity appears disrupted. Single nucleotide polymorphisms 
in the promoter region of the CHRNA7 gene, the gene that encodes the α7 protein, are a risk 
factor in the development of schizophrenia (Leonard et al., 2002). In individuals who develop 
schizophrenia, a decrease in both α7 protein, and in some populations, decreases in mRNA 
expression have been reported (Guan et al., 1999; Matthew et al., 2007). Additionally, kynurenic 
acid, a tryptophan metabolite, is an endogenous antagonist to the α7nAChR and has been found 
to be elevated in cerebrospinal fluid and postmortem brains of patients with schizophrenia 
(Hilmas et al., 2001; Linderholm et al., 2012; Schwarcz et al., 2001). Given the importance of 
α7nAChR activity in cognition, decreased α7nAChR activity may contribute to the cognitive 
deficits and glutamate hypofunction seen in schizophrenia.  
Nicotine, the primary drug found in tobacco products, is a direct agonist of the α7nAChR 
and has limited pro-cognitive effects. Interestingly, between 60 and 90% of patients with 
schizophrenia smoke cigarettes (Leonard et al., 2001). This staggering correlation has led some 
to believe that increased nicotine consumption is a form of self-medication to alleviate cognitive 
deficits that are not managed with current treatment regimens (Leonard et al., 2007). 
Unfortunately, nicotine is not an ideal therapeutic for treating cognitive deficits for a variety of 
reasons: the pro-cognitive effects of nicotine are short-lived, as the α7nAChR receptor is easily 
desensitized; nicotine is not selective to the α7nAChR, leading to many side effects; and many 
negative health effects of nicotine products (Papke et al. 2009). As a result, direct α7nAChR 
agonists have been developed which can reduce cognitive symptoms in animal models of 
schizophrenia (Hauser et al., 2009). Additionally, pro-cognitive effects α7nAChR agonists have 
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been demonstrated in human populations (Olincy et al., 2006). The tendency for the α7nAChR 
receptor to desensitize has prompted investigation into low-dose agonists, which have shown 
benefits in animal models of cognitive deficits (Werkheiser et al., 2011). While selective 
α7nAChR agonists, particularly at low doses, may have advantages over the use of nicotine, they 
may still be limited to characteristics inherent to direct agonists. 
There are two primary fundamental limitations of direct agonists as 
pharmacotherapeutics. First, direct agonists bind to the receptor and cause a response when 
present in a system. This indiscriminant activation occurs with or without afferent activity, 
leading to the tendency to cause false alarms at the receptor. Second, direct agonist activity does 
not preserve the temporal integrity of endogenous neurotransmission, which may be important to 
many neural processes underlying cognitive performance. In other words, neural connections 
lose the degree-of-freedom afforded by the ability to selectively activate and deactivate the 
receptor as is biologically-relevant. Instead, direct agonists reduce this complexity to an “always 
on” signal while the agonist is present in the brain. Due to the disruptions of native spatial and 
temporal signaling caused by direct agonism, a more subtle method of enhancing receptor 
activity is needed that maintains the complexity of the neural system. 
Positive allosteric modulators (PAMs) are chemicals that enhance receptor activity in the 
presence of an orthosteric ligand, while in the absence of an orthosteric ligand, have no intrinsic 
receptor activity. Unlike orthosteric agonists, which bind to the same location as the endogenous 
neurotransmitter, positive allosteric modulators bind at a different site, termed allosteric site. 
Binding at the allosteric site allows PAMs to alter the receptors configuration and, therefore, 
activity at the orthosteric site. In this manner, PAMs are able to enhance receptor activity in the 
presence of an orthosteric ligand; however, binding to the allosteric site in the absence of 
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orthosteric activity does not result in a receptor response. In the case of α7nAChRs, PAMs do 
not cause cation influx in the absence of orthosteric activity. 
α7nAChR PAMs are now being investigated as pro-cognitive therapeutics with potential 
in ameliorating deficits in diseases such as schizophrenia. Several α7nAChR PAMs have been 
used either alone or in conjunction with drugs that increase α7nAChR orthosteric activity to 
ameliorate cognitive deficits and sensory gating deficits in several animal models of 
schizophrenia (Hurst et al., 2005; Ng et al., 2007; Thomsen et al., 2011; McLean et al., 2012; 
Callahan et al., 2013). Additionally, α7nAChR PAMs have been shown to potentiate evoked 
excitatory amino acid release in vitro and evoked prefrontal dopamine release in vivo (Zwart et 
al., 2002; Livingstone et al., 2010). α7nAChR PAMs fall into two categories: type I and type II. 
The PAM types differ in that type I PAMs affect peak current, whereas type II PAMs affect both 
peak current and current decay (Grønlien et al., 2007). That is, both types increase the peak 
amount of cation influx, but while type I PAMs allow the receptor to naturally desensitize into a 
closed configuration, type II PAMs prevent the receptor from entering this desensitized state and 
allow the receptor to remain open with continued cation influx (Williams et al., 2011a). 
Furthermore, only type II PAMs have been shown to reactivate desensitized α7nAChRs (Hurst et 
al., 2005; Grønlien et al., 2007). While interest has been growing in the use of α7 PAMs for a 
variety of neurological disorders, limited research has been published characterizing effects on 
neurotransmitter systems in vivo. 
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Research Overview 
Mesolimbic Stimulation Assay 
In order to investigate the effect of PAMs, the drug must be applied in the presence of the 
neurotransmitter that is modulated, as PAMs have no effect on receptor activity in the absence of 
orthosteric activity. Both task- and chemical-induced activity in the nucleus accumbens (NAc) 
have been previously shown to cause increases in both prefrontal cholinergic and glutamatergic 
activity (Neigh et al., 2004; Zmarowski et al., 2007; Bortz et al., 2014). Similarly, NMDA 
infusion into the anterior shell of the nucleus accumbens dose-dependently increases prefrontal 
choline, a selective α7nAChR agonist, and glutamate (Alkondon et al., 1997; Bortz et al., 
unpublished data). NMDA-evoked glutamate release is dependent on α7nAChR activity, as 
antagonism of the α7nAChR abolishes this evoked release (Bortz et al., unpublished data). 
Therefore, differing concentrations of NMDA infused into the accumbens cause different 
concentrations of acetylcholine to be released in the prefrontal cortex. These varying 
concentrations of acetylcholine activate the α7nAChR, facilitating glutamate release dose-
dependently as a function of the concentration of acetylcholine. Thus, with this assay, the effects 
of α7nAChR PAM can be assessed in the presence of endogenously released acetylcholine 
without disrupting the integrity of cholinergic transmission in the PFC. Additionally, this assay is 
a model of top-down cognitive processing and is capable of rescuing failing performance during 
the distractor portion of sustained attention tasks (St. Peters et al., 2011). 
Aims 
The goal of this experiment is to assess the ability of different doses of both type I and 
type II α7nAChR PAMs, AVL-3288 and PNU-120596 respectively, in potentiating glutamate 
release in vivo as a function of choline release in awake, freely moving rats. 
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Hypothesis 
If cholinergic activity is required for PAMs to enhance activity at the orthosteric site of the 
α7nAChR, then each PAM will potentiate prefrontal glutamate release as a result of mesolimbic 
stimulation, but not under basal conditions. 
Experimental Design 
Animals were tested on three consecutive test days, receiving the same concentration of 
NMDA stimulation on each day. Prior to NMDA stimulation, animals were systemically injected 
with either AVL-3288 or PNU-120596. Dose of PAM was manipulated between test days so that 
the effect of either high-dose PAM, low-dose PAM, or vehicle on a constant level of stimulation 
could be measured. Each subject only received one type of PAM for experiments. The effects of 
each dose of PAM were compared to the glutamate release on the vehicle test day. Using this set-
up, an increase or decrease in glutamate release from the vehicle test day in the presence of PAM 
could be observed as a potentiation or attenuation, respectively, within subject. 
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Methods 
Microelectrode Array: Second-by-Second Measurements of Glutamate 
Self-referencing, ceramic-based, multisite microelectrode arrays (MEA) were used for 
the detection of in vivo glutamate release in awake, freely-moving rats (Quanteon, LLC, 
Nicholasville, KY)(see figure 1). Each MEA consists of two pairs of platinum recording 
channels (15 x 333µm each) separated 100µm vertically and 30µm horizontally. The highly-
selective enzyme, glutamate oxidase (GluOx, 2%, 1 unit/µL, 100nL) was cross-linked to the first 
pair of recording channels using glutaraldehyde (0.125%) and bovine serum albumin (BSA; 1%). 
GluOx oxidizes glutamate, producing α-ketoglutarate, ammonia, and hydrogen peroxide (H2O2). 
H2O2, which is electrically active at the applied voltage, serves as the reporting molecule for 
glutamate. H2O2 is oxidized at the platinum recording site due to an electric potential of +0.7V 
relative to a Ag|AgCl reference electrode, placed distant from the recording site. The oxidation 
of H2O2 produces a current, which is amplified and recorded using the FAST-16 mkII recording 
system (Quanteon, LLC, Nicholasville, KY). This amperometric design allows for sub-second 
temporal resolution of the MEA. By calibrating each MEA in vitro prior to implantation, the in 
vivo concentration of glutamate can be derived from the recorded current. The second pair of 
recording channels, coated in only glutaraldehye and BSA but lack GluOX, is not glutamate-
sensitive and serves as a background, or sentinel, channel, recording signals that are not 
glutamate-driven. The glutamate-sensitive channels are self-referenced with the sentinel 
channels, isolating the signal derived exclusively from glutamate (Burmeister & Gerhardt, 2001; 
Day et al., 2006; Rutherford et al., 2007). In order to minimize the signal from oxidizable 
interferents, such as dopamine or ascorbic acid, m-phenylenediamine dihydrochloride (mPD) 
was electroplated onto the recording sites prior to sensor calibration and implantation. mPD 
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serves as a physical barrier, preventing larger molecules, such as catecholamines and ascorbic 
acid, from interacting with the recording site, while smaller molecules, such as H2O2, are not 
excluded (Wahono et al., 2012). The exclusion barrier in conjunction with the self-referencing 
technique allow each MEA to be highly selective for glutamate with a limit of detection less than 
0.5µM. MEAs can remain selective and sensitive to glutamate for up to seven days of chronic 
recording (Rutherford et al., 2007). 
Sensor Calibration: in vitro 
Immediately prior to sensor implantation, the microelectrodes were calibrated in vitro in 
a solution of PBS (0.05 M, 40 mL; pH 7.4; 37°C; +0.7 V). After baseline was established, 
channel signals were recorded at a rate of 1 Hz following the addition of ascorbic acid (250 µM), 
glutamate (3 x 20 µM), dopamine (2 mM), and hydrogen peroxide (8.8 µM) (see fig. 2). The 
effectiveness of the mPD barrier was assessed by observing no change in measurement on any of 
the four channels during the addition of ascorbic acid or dopamine, both of which can be found 
in high concentrations in vivo and are electrically active at the sensor’s applied voltage (Lowry & 
O’Neill, 1992). When glutamate was added, an increase in current was observed on the two 
GluOx channels. The slope (nA/µM glutamate) was determined from these three glutamate 
additions in order to relate the measured current to the glutamate concentration when used in 
vivo. The final addition of hydrogen peroxide created a current observable on all four channels to 
ensure all channels are equally sensitive to the reporting molecule. In order to qualify for use, 
every sensor must have met the following criteria: (i) no difference greater than 20 pA during 
background current between all four channels, (ii) linear response to increase in glutamate 
concentration with a coefficient of determination (r
2
) value greater than 0.998, (iii) high 
sensitivity, determined by a slope greater than -0.003 nA/µM glutamate, (iv) a limit of detection 
Upton 21 
 
 
<0.5 µM, (v) high selectivity of glutamate to ascorbic acid and dopamine (>50:1), and (vi) 
greater than 80% but less than 125% similarity to hydrogen peroxide for channel pairings. 
Experimental Subjects 
All measurements were done in adult male Wistar rats (body weight 280-420 g; Charles 
River Laboratory: Wilmington, MA). Animals were housed in individual plastic cages with corn 
cob bedding (Harlan Teklad, Madison, WI) in a temperature (72°) and humidity (30-70%) 
controlled room on a 12:12 light:dark cycle. All animals had access to food and water ad libitum. 
All procedures involving animals were approved by The Ohio State University Institutional 
Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. As such, all efforts were made to minimize animal suffering, to reduce the 
number of animals used, and to consider alternatives to in vivo techniques. 
Implantation of Microelectrode and Infusion Cannulae 
Animals were anesthetized using isoflorane gas (2%, 0.6 L/min) and positioned with a 
stereotax. An MEA was placed unilaterally between infralimbic and prelimbic cortices of the 
medial prefrontal cortex (in mm from bregma: AP +2.7, ML ±0.65, DV -4.0; hemispheres 
counterbalanced; see fig. 3A and 3B). A steel guide cannula used for intracoritcal infusions of 
NMDA was placed in the anterior shell of the nucleus accumbens, ipsilateral to the MEA (in mm 
from bregma: AP +0.4, ML ±0.70, DV -6.4; see fig. 3C and 3D). The infusion cannula extended 
1.0 mm farther than the guide cannula and when not in place, a dummy cannula was inserted, 
extending 0.7 mm past the tip of the guide cannula. The Ag|AgCl reference electrode was placed 
in the contralateral parietal lobe, distant from the MEA. The atlas of Paxinos and Watson (1998) 
was used to determine all coordinates. The sensor was secured using three stainless steel screws 
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mounted to the skull and dental acrylic (DuraLay Inlay Pattern Resin). Animals were not tested 
until the second day after surgery to allow time to recover. 
In vivo Recordings and Drug Administration 
The day following implantation surgery, the rats habituated to their testing environment, 
a wooden test box (16” width, 16” length, 24” height) with corn cob bedding inside a Faraday 
cage, but were not connected to the sensor’s preamplifier. On the following days, the animals 
were placed into the testing box and connected to the preamplifier and a baseline recording was 
established for a minimum of two hours before the infusion of any drugs. Prior to NMDA 
infusion, rats were pretreated with an intraperitoneal injection of AVL-3288 (1 or 3 mg/kg) or 
PNU-120596 (3 or 9 mg/kg) or vehicle (dimethyl sulfoxide (DMSO), 5% by volume; Solutol®, 
8% by weight). Thirty minutes after PAM pretreatment, artificial cerebrospinal fluid (aCSF; pH 
7.1-7.4) was infused into the NAc to serve as a positive control as well as to clear the cannula 
and guide cannula prior to drug administration. Ten minutes after aCSF infusion, NMDA (0.05 
or 0.30 µg/0.5 µL aCSF) was infused into the NAc. A Hamilton PB600-1 manual dispenser was 
used to deliver aCSF and NMDA through the cannula over two seconds. Dose of PAM was 
manipulated within subjects between test days, while the dose of NMDA was consistent between 
test days and was only manipulated between subjects. The dose order of PAMs was 
counterbalanced among animals. 
Histology 
All MEA and cannula placement was verified post mortem. Following the third test day, 
rats were given an overdose of pentobarbital sodium and transcardially perfused with heparinized 
saline (0.2%) followed by formalin (10%). Brains were removed and were placed in formalin for 
a minimum of three days at 4°C. One day prior to sectioning, the brains were moved to a sucrose 
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solution (30%) and maintained at 4°C. The sucrose solution serves as a cryoprotectant to prevent 
artifacts as a result of freezing the tissue samples. Brains were sectioned into coronal slices 
(50µm) using a cryostat (-25°C), mounted on gelatin-coated slides, and stained using cresyl 
violet. Slices were examined under a light microscope to determine sensor and cannula 
placement. If MEA placement into the mPFC or cannula placement into the anterior NAcSh 
could not be verified, the data from the animal was excluded from analysis (see figure 3 for 
sample MEA and cannula placement). 
Data Analysis 
Measurements derived from the MEA recording and the FAST-16 data file included: (i) 
basal glutamate levels, (ii) maximum peak concentration (uM) of glutamate, (iii) the latency 
(second) of onset of the effect from the time of drug infusion, and (iv) T80, the time in seconds 
from maximum peak amplitude to 80% decay of signal (a measure of glutamate clearance). The 
signal derived exclusively by the oxidation of glutamate was isolated using a self-referencing 
procedure between the glutamate-sensitive recording channel and the adjacent background 
sentinel channel (Burmeister and Gerhardt, 2001; Day et al., 2006; Rutherford et al., 2007). All 
dependent measures will be analyzed by analysis of variance (ANOVA) using the SPSS 18 
statistics program (V19, IBM Corporations, Armonk, NY). In all ANOVAs, the Huynh-Feldt 
correction will be utilized to reduce type I errors associated with repeated measure ANOVAs 
(Vasey and Thayer, 1987). Statistical significance was defined as P < 0.05. 
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Results 
AVL-3288 Results 
Effects of AVL-3288 on basal glutamate 
Basal glutamate, measured after IP injection but before aCSF infusion, did not vary 
between AVL-3288 dose (F2,28=3.134, p=0.068) or NMDA dose (F1,9=1.031, p=0.395) and there 
was no interaction between the dose combinations (F4,18=0.321, p=0.860). These results indicate 
that systemic injection of AVL-3288 does not affect basal glutamate release, i.e. in the absence 
of stimulation. 
Effects of AVL-3288 on evoked glutamate 
The type I α7nAChR PAM, AVL-3288, was injected systemically 40 minutes prior to 
mesolimbic-stimulation with NMDA. The dose of NMDA (0.05µg and 0.30µg) was held 
constant across test days and was administered in the presence of vehicle, low-dose, and high-
dose of AVL-3288. With this setup, effects of dose of AVL-3288 will be presented as a percent 
change from the vehicle test day. In this manner, a positive percent change signifies that more 
glutamate was released in the presence of AVL-3288 with the same level of stimulation (i.e. 
concentration of NMDA), while a negative percent change signifies that less glutamate was 
released in the presence of AVL-3288 than on the vehicle-treated day.  
Two-way (AVL dose x NMDA dose) omnibus ANOVA revealed a significant effect on 
the percent change in glutamate release between AVL-3288 dose (F2,28=9.128, p=0.001) and an 
AVL dose-NMDA dose interaction (F4,28=5.008, p=0.04). Subsequent one-way ANOVA on dose 
of AVL-3288 (vehicle, 1 mg/kg, 3 mg/kg) revealed a significant difference between AVL doses 
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within the 0.30 NMDA group (F2,14=11.873, p=0.001), but not within the 0.05 NMDA group 
(F2,17=0.494, p=0.620). Within the high-dose of NMDA group, percent change in glutamate 
release was significantly potentiated by 1 mg/kg AVL-3288 compared to the vehicle response 
(F1,9=5.932, p=0.41) with an average percent change of 84.70 ± 34.78%. Conversely, the percent 
change in glutamate release was significantly attenuated by 3 mg/kg AVL-3288 with respect to 
vehicle response (F1,9=20.575, p=0.002) with an average percent change of -64.24 ± 14.16%. 
The percent change of glutamate release also varied between 1 mg/kg and 3 mg/kg AVL-3288 
(F1,9=15.732, p=0.004). An additional one-way ANOVA on dose of NMDA (aCSF, 0.05µg, 
0.30µg) revealed an interaction within the 1mg/kg AVL-3288 treated group (F2,16=5.661, 
p=0.016) but not within the 3mg/kg AVL-3288 treated group (F2,16=1.953, p=0.179). 1 mg/kg 
AVL-3288 potentiated glutamate release more after 0.05µg compared to aCSF (F1,11=17.471, 
p=0.002) and more after 0.30µg compared to aCSF (F1,10=7.280, p=0.024). Thus, 1 mg/kg AVL-
3288 produced a percent change of 24.12 ± 5.77% after 0.05µg stimulation. Lastly, additional 
two-way (AVL dose x NMDA dose) ANOVAs did not reveal any variation among latency to 
peak onset, T50, T80, and peak duration (all p-values >0.1). 
Fig. 4 demonstrates representative line tracings for an animal receiving 0.05µg/0.5 µL 
NMDA in the presence of vehicle and 1 mg/kg AVL3288. Time is represented on the X-axis and 
glutamate concentration is represented on the Y-axis. Infusions of aCSF or NMDA into the 
nucleus accumbens are denoted with arrows. The top line tracing is the signal produced from the 
glutamate-sensitive channels, whereas the line tracing beneath is from the sentinel channels, 
which lack GluOx. The bottom tracing is the self-referenced tracing, which represents the signal 
derived solely from the oxidation of glutamate and is obtained by subtracting the sentinel signal 
from the glutamate signal. This sample tracing from an individual animal demonstrates an 
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increase of 2.83µM glutamate from low-dose NMDA stimulation during the vehicle test day. 
However, when pretreated with 1 mg/kg AVL-3288, the low-dose NMDA produced a 
potentiated response of 3.46 µM, a percent change of 22%.  
Fig. 5 is a representative tracing from an animal receiving high-dose NMDA stimulation 
and vehicle and high-dose AVL-3288 injections. For simplicity, only the self-reference tracing is 
shown. After vehicle injection, the high-dose of NMDA produced a 9.44 µM increase in 
glutamate. When pretreated with the high-dose of AVL-3288, the high dose NMDA response 
was attenuate and only 7.16µM was evoked, a percent change of -24%.  
Overall, AVL-3288 differentially modulates NMDA-evoked glutamate release in the PFC 
as a function of dose of NMDA. At the low-dose of NMDA, the low-dose of AVL-3288 
significantly potentiates glutamate release, but at the high-dose of AVL-3288, glutamate was not 
potentiated. At the high-dose of NMDA, glutamate release was significantly potentiated with the 
low-dose of AVL-3288, but significantly attenuated at the high-dose of AVL-3288. Group data 
for the dose combinations is presented in Fig. 6 as a percent change from vehicle test days. 
Absolute increases of glutamate from aCSF, low-dose NMDA, and high-dose NMDA on vehicle 
test days are presented in the inset graph for reference to percent change.  
PNU-120596 Results 
Effects of PNU-120596 on basal glutamate 
Basal glutamate, measured after IP injection but before aCSF infusion, did not vary 
between PNU-120596 dose (F2,30=1.704, p=0.207) or NMDA dose (F1,15=0.580, p=0.572) and 
there was not an interaction between the dose combinations (F2,30=0.332, p=0.804). These results 
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indicate that systemic injection of PNU-120596 does not affect basal glutamate release, i.e. in the 
absence of stimulation. 
Effects of PNU-120596 on evoked glutamate 
The type II α7nAChR PAM, PNU-120596, was injected systemically 40 minutes prior to 
mesolimbic-stimulation with NMDA. Similar to AVL-3288 experiments, dose of NMDA 
(0.05µg or 0.30µg) was held constant between test days in the presence of vehicle, 3 mg/kg, and 
9 mg/kg PNU-120596. Data will be presented as a percent change from NMDA-evoked 
glutamate release after vehicle treatment.  
Two-way (PNU dose x NMDA dose) omnibus ANOVA revealed a significant effect on 
the percent change in glutamate release between PNU-120596 dose (F2,30=11.43, p<0.001) and 
NMDA dose (F1,15=7.260, p=0.006) and an AVL dose-NMDA dose interaction (F4,30=7.020, 
p<0.001). Subsequent one-way ANOVA on dose of PNU-120596 (vehicle, 3 mg/kg, 9 mg/kg) 
revealed a significant difference between PNU doses within the 0.05 NMDA group (F2,17=9.128, 
p=0.003), but not within the 0.30 NMDA group (F2,17=0.822, p=0.458). Within the low-dose 
NMDA group, 9 mg/kg PNU-120596 significantly potentiated glutamate release more than both 
vehicle (F1,11=17.404, p=0,002) and 3 mg/kg PNU-120596 (F1,11=6.958, p=0.025); however, 3 
mg/kg PNU-120596 did not significantly potentiate glutamate release over vehicle (F1,11=1.153, 
p=0.308). 9 mg/kg PNU-120596 potentiated 0.05µg by 211.95 ± 50.80% when compared to 
glutamate evoked by 0.05µg after vehicle pretreatment. An additional one-way ANOVA on dose 
of NMDA (aCSF, 0.05µg, and 0.30µg) revealed an effect of the 9 mg/kg PNU-120596 
(F2,17=9.827, p=0.002), but not 3 mg/kg PNU-120596 (F2,17=0.917, p=0.421) on percent change 
of evoked glutamate release. 9 mg/kg PNU-120596 significantly potentiated glutamate release 
after 0.05µg NMDA more than after aCSF (F1,11=17.404, p=0.002) and 0.30µg NMDA 
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(F1,11=7.788, p=0.019). Lastly, two-way (PNU dose x NMDA dose) ANOVAs did not reveal any 
variation among latency to peak onset, T50, T80, and peak duration (all p-values >0.7). 
Fig. 7 demonstrates a representative self-tracing for low-dose NMDA stimulation after 
the pretreatment of vehicle and 9 mg/kg PNU-120596. The glutamate response of 1.72µM on the 
vehicle test day was potentiated to 4.27µM on the high-dose PNU-120596 test day, a percent 
change of 148%. 
Overall, PNU-120596 differentially modulates NMDA-evoked glutamate release in the 
PFC as a function of dose of NMDA. At the low-dose of NMDA, the high-dose of PNU-120596 
significantly potentiates glutamate release, whereas at the low-dose of PNU-120596, glutamate 
was not potentiated. Interestingly, at the high-dose of NMDA, glutamate release was not 
potentiated with the low-dose of PNU-120596 or high-dose of PNU-120596 nor was it 
attenuated at either dose. Group data for the dose combinations is presented in Fig. 8 as a percent 
change from vehicle test days. Absolute increases of glutamate from aCSF, low-dose NMDA, 
and high-dose NMDA on vehicle test days are presented in the inset graph for reference to 
percent change. 
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Discussion 
Several lines of evidence indicate that the signal measured by the MEA is glutamate-
derived. Reducing the applied potential from +0.7V to +0.2V eliminates the sensor’s ability to 
record glutamate as the reporting molecule, H2O2, is not electrically active at this lower potential 
(Pomerleau et al., 2003; Day et al., 2006). In this circumstance, glutamate is being oxidized, but 
the H2O2 produced is unable to be reduced to generate a signal. While such experiments establish 
that the potential must be at large enough to reduce H2O2 in order to measure glutamate, they do 
not establish that the H2O2 is produced from the oxidation of glutamate. Although GluOx is a 
highly selective enzyme, further determination of the signal as glutamate-derived can be 
accomplished by altering glutamate kinetics. Application of a glutamate uptake inhibitor, TBOA, 
causes an increase in glutamate signal and clearance time (Pomerleau et al., 2003; Bortz et al., 
2013). These increases in signal and clearance time reflect extracellular glutamate persisting due 
to the inhibition of glutamate transporters. Similarly, enhancing glutamate transporters with 
ceftriaxone leads to a decrease in clearance time as glutamate is cleared more rapidly (Bortz et 
al., 2013). Furthermore, stimulating mGluR2/3, a glutamate autoreceptor, decreases glutamate 
signal as less glutamate is released and antagonism of the mGluR2/3 results in an increase of 
glutamate signal because more glutamate is released (Hascup et al., 2010). Together, this 
evidence suggests that the MEA used in the experiments for this study was capable of measuring 
glutamate release in vivo.  
In addition to measuring glutamate in vivo, the MEA measures glutamate that is 
neuronally-derived. Local application of ω-conotoxin (MCVIIC) blocks the influx of calcium 
through calcium channels, inhibiting exocytocic release of neurotransmitters at the axon terminal 
and decreasing basal glutamate measured with the MEA (Hascup et al., 2010). Unlike glutamate 
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measured via microdialysis, glutamate measured with the MEA is tetrodotoxin (TTX)-sensitive 
(Day et al., 2006; van der Zeyden et al., 2008; Hascup et al., 2010). TTX blocks sodium 
channels, preventing action potentials; so, insensitivity to TTX indicates that the signal is not 
neuronally-derived, whereas a signal that is neuronally-derived would be affected by this 
inhibition. This discrepancy between microdialysis and the MEA TTX-sensitivity is likely due to 
differing amount of damage caused by either structure. The microdialysis probe causes more 
tissue damage and gliosis than the MEA, leading to more microglial and astrocytic activation 
(van der Zeyden et al., 2008; Hascup et al., 2009). Blocking the cysteine-glutamate exchanger, 
an antiporter located primarily on glia, with (S)-4-carboxyphenylglycine (CPG) reduces 
glutamate measured by microdialysis, but not glutamate measured by the MEA (Hascup et al., 
2010). Therefore, due to increased glial activation by the microdialysis probe, microdialysis 
techniques may measure non-neuronal pools of glutamate, whereas the MEA measures from 
neuronal pools with no detectable glutamate measurements from cysteine-glutamate transporters. 
Using an MEA that measures neuronally-derived glutamate, the results from this study 
demonstrate for the first time the ability of α7nAChR PAMs to potentiate glutamate release in 
vivo and additionally, in awake, freely-moving rats. Previous studies investigating PAMs have 
been limited to in vitro measurements or in vivo recordings of dopamine in anesthetized animals. 
Many in vitro study findings may have limited implications as it has recently been demonstrated 
that the type II PAMs PNU-120596 and SB-206553 are considerably less potent at physiological 
temperatures than at the room temperature, which is the temperature that the majority of in vitro 
experiments occurred (Sitzia et al., 2011). This study demonstrates that in vivo, i.e. physiological 
temperatures, both AVL-3288 and PNU-120596 were capable of modulating neurotransmitter 
release. The effect of increased temperature on α7nAChR activity is more pronounced at higher 
Upton 33 
 
 
agonist concentration, as the percent decrease in current amplitude as a result of increased 
temperature is more significant at maximal concentrations than at EC50 (Jindrichova et al., 2012). 
Additionally, maximal concentration of agonist caused a more rapid desensitization at 
physiological temperatures than at room temperature, whereas temperature had no effect on 
desensitization from agonist at EC50 (Jindrichova et al., 2012). Two distinct desensitized states 
have been proposed for the α7nAChR, one that is destabilized by PNU-120596 and one that is 
not destabilized by PNU-120596 (Williams et al., 2011a). This ability to destabilize a 
desensitized receptor configuration may underlie the capability for type II PAMs to block 
desensitization. However, the second desensitized state proposed by Williams et al. was 
insensitive to PNU-120596. Greater free energy at physiological temperatures may favor the 
PNU-120596-insensitive desensitized state over the PNU-120596-sensitive desensitized state and 
contribute to reduced efficacy of type II PAMs at physiological temperatures. The existence of 
multiple desensitized states may also contribute to differences demonstrated in vivo between the 
type I PAM, AVL-3288, and the type II PAM, PNU-120596, at the higher dose combinations in 
this study.  
Glutamate signal was attenuated with high levels of NMDA-stimulation in the presence 
of the high-dose of AVL-3288. This may reflect rapid receptor desensitization as a result of 
interaction between a high concentration of acetylcholine and a high concentration of AVL-
3288. These results are not surprising as AVL-3288 is a type I PAM and, therefore, should have 
no effect on receptor desensitization. Notably, AVL-3288 was originally developed by screening 
GABAA PAMs to find an initial template for an α7nAChR PAM and was then modified to 
increase selectivity to the α7nAChR and enhance bioavailability (Ng et al., 2007). While AVL-
3288 does not have activity at other nicotinic receptors, e.g. α4β2 and α3β4, the PAM still has a 
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low affinity as a GABAA PAM (Ng et al., 2007). Activity at this receptor may contribute to 
glutamate attenuation, however, is likely not the sole cause of the response. If GABAA activity 
alone was sufficient to significantly attenuate the glutamate response, then a significant 
attenuation should have been observed when the low-dose of NMDA-stimulation was given in 
the presence of the high dose of AVL-3288. Because the high-dose of AVL-3288 was not 
sufficient to attenuate glutamate, the high-dose must interact with the higher NMDA-stimulation 
to reduce the recorded signal. While α7nAChR desensitization is a plausible and likely 
explanation of the phenomenon, increased GABA activity cannot be excluded as GABA is 
primarily an inhibitory neurotransmitter and can reduce glutamate transmission. Although it has 
not been reported, if mesolimbic stimulation with NMDA dose-dependently increases GABA as 
well as choline and glutamate, then positive allosteric modulation of GABAA could lead to 
increased inhibitory effects at higher levels of NMDA-stimulation. Although, if GABA activity 
does not vary between levels of NMDA-stimulation, then the increased attenuation observed at 
higher concentrations of NMDA-stimulation is more likely desensitization or some other 
interaction between the dose of AVL-3288 and the increased stimulation. When tested on 
oocytes, i.e. in the absence of GABA, AVL-3288 exhibited an attenuated response in the 
presence of continued stimulation, indicating that desensitization of the α7nAChR in the 
presence of AVL-3288 occurs independent of its GABA activity. While the extent of the 
interaction of GABA and AVL-3288 in vivo is not yet known, a clear interaction occurs between 
the high-dose combination of AVL-3288 and NMDA stimulation that results in an attenuation of 
evoked glutamate release and this attenuation likely involves α7nAChR desensitization. 
In contrast to AVL-3288, PNU-120596 did not cause a significant attenuation in 
glutamate release at any dose-combinations tested. Although, at higher doses of NMDA, the 
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ability of PNU-120596 to potentiate glutamate was diminished; however, the signal was not less 
than after vehicle pretreatment. This result is consistent with a PNU-120596-insensitive 
desensitized state (Williams et al., 2011a). An alternate explanation to the decreased 
effectiveness of PNU-120596 is open channel block by large cations. While the α7nAChR gates 
cations, large cations, such as choline, are too large to flow through the channel pore and 
consequently, can block the influx of smaller cations, such as Ca
2+
 or Na
+
 (Kalappa & Uteshev, 
2013). By preventing PNU-120596-sensitive desensitization, the kinetics of the α7nAChR is 
altered and the channel stays open for longer durations (Hurst et al., 2005; Szabo et al., 2014). 
The increased duration of channel opening increases the probability that the channel will be 
blocked by large cations, resulting in open-channel inhibition. Additionally, PAMs generally 
have a saturability of their effects due to a limited degree of cooperativity between orthosteric 
and allosteric binding sites, producing diminishing returns with increased orthosteric-allosteric 
saturation (Christopolous, 2002; Uteshev, 2014a). Together, these mechanisms may contribute to 
the diminished ability of PNU-120596 to potentiate glutamate release, despite the ability of 
PNU-120596 to prevent rapid desensitization.  
Behaviorally, the lack of potentiation at high levels of stimulation with PNU-120596 may 
not be relevant. PAMs may be most advantageous when enhancing signal that has low salience. 
If the signal is strong, i.e. high salience, the signal likely will not need to be further enhanced and 
positive modulation may not be necessary; therefore, the differential ability to potentiate high 
levels of stimulation between types of PAMs may not cause changes in cognitive performance. 
More importantly, both types of PAMs demonstrate the ability to potentiate low-dose stimulation 
in vivo. While enhancing low levels of α7nAChR activity may be essential in enhancing 
glutamate release in order to ameliorate cognitive deficits, PAMs may also increase the risk of 
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inappropriately activating the receptor in the presence of a subthreshold stimulus. This false 
alarm would be the result of potentiating a signal that would have not otherwise generated a 
response. Indeed, PAMs can enable receptor activity in the presence of concentrations of 
acetylcholine that did not previously induce activity (Hurst et al., 2005). This fine line between 
enhancing cholinergic function in a state of hypofunction and avoiding false alarms may limit the 
therapeutic advantage of using PAMs over orthosteric agonists. This is not to say that PAMs will 
not have advantages over orthosteric agonists, but rather PAMs will inherently cause some 
inappropriate receptor activation, although likely to a lesser extent than orthosteric agonists. This 
effect is because PAMs require a minimal amount of orthosteric activity in order to produce a 
response, even if the afferent activity is subthreshold in the absence of PAM, whereas orthosteric 
agonists will indiscriminately activate the receptor, even in the absence of any afferent activity. 
Thus, the ability to potentiate highly salient stimuli, or lack thereof, may not influence PAM 
efficacy in behavioral tasks; although, PAMs can potentiate stimuli with low salience, but may 
be limited in their advantage over orthosteric agonists due to their ability to potentiate 
subthreshold stimuli.  
The differential effect on rapid desensitization between the two types of PAMs may also 
affect the therapeutic advantage of PAMs. By blocking one form of receptor desensitization, 
PNU-120596 allows for an increased receptor response and more calcium entry into the neuron. 
As such, the potentiation of glutamate by PNU-120596 was far more robust than the potentiation 
measured in the presence of AVL-3288. While these results are intriguing, it will be interesting 
to see which type of PAM produces more advantageous results in behavioral tasks. While 
increased glutamate release is generally construed as beneficial, too much can cause excitotoxic 
damage. Thus, desensitization of the α7nAChR may serve to protect the brain from destructive 
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levels of stimulation. At room temperature, PNU-120596 was cytotoxic to cell lines and this 
damage was dependent on α7nAChR activity (Ng et al., 2007). However, when tested at 
physiological temperatures, PNU-120596 did not demonstrate excitotoxicity (Hu et al., 2009; 
Sitzia et al., 2011). Although PNU-120596 likely does not decrease cell viability in vivo likely 
due to increased temperature, AVL-3288 did not cause damage to cells at any temperature 
measured, including at room temperature where the drugs and receptor have significantly 
increased activity (Ng et al., 2007). Therefore, type II PAMs may have more potential to 
exacerbate excitotoxic events than type I PAMs due to differential effects on rapid 
desensitization. Receptor desensitization is also important for agonist-induced α7nAChR up-
regulation and by blocking desensitization, PNU-120596 prevents this up-regulation of the 
receptor (Thomsen & Mikkelsen, 2012). However, increased α7nAChR expression did not 
correlate with cognitive improvements in these experiments, although localization of receptors 
on the surface versus within the cell was not determined (Thomsen et al., 2011). In addition to 
these differences between type I and type II PAMs based on receptor desensitization, the results 
presented here demonstrate differential effects of type I and type II PAMs in evoking glutamate 
release at high-dose combinations. Further behavioral studies are needed to determine if these in 
vivo differences produce different results in behavioral tasks and if the inhibition of 
desensitization is more or less beneficial to cognitive performance. 
If the goal of PAMs is to enhance endogenous cholinergic activity, then type I PAMs 
better preserve the nature and integrity of cholinergic transmission. While type II PAMs may 
produce more robust effects, they also alter α7nAChR kinetics and allow the channel to be open 
for a longer duration. Type I PAMs, conversely, have no effect on receptor kinetics and as such, 
receptor dynamics with low concentrations of acetylcholine and type I PAM are similar to 
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receptor dynamics with higher concentrations of acetylcholine (Ng et al., 2007). Regardless of 
the effect of receptor kinetics, both types of PAM have demonstrated pro-cognitive effects in 
sensory gating, working memory, spatial memory, short-term memory, and cognitive flexibility 
(Hurst et al. 2005; Ng et al., 2007; Timmerman et al., 2007; Dunlop et al., 2008; Faghih et al., 
2009; McLean et al., 2012). Despite the promising effects of α7nAChR PAMs in preclinical 
studies, the type II PAM, JNJ-39393406, failed to reduce sensory gating deficits in patients with 
schizophrenia when used as an adjunct to antipsychotic treatment (Winterer et al., 2013). In this 
phase II trial, the PAM was administered acutely. Several preclinical studies have failed to 
demonstrate an improvement in cognitive performance when administering a PAM alone and 
acutely (Thomsen et al., 2011; Callahan et al. 2013). It may be that some of the PAMs, 
particularly type II, require multiple administrations before pro-cognitive effects can be observed 
and that immediate facilitation of α7nAChR activity may not always be sufficient to enhance 
cognitive performance. Although they may not always be effective when administered alone, 
PAMs can be used in conjunction with other drugs that increase orthosteric activity at the 
α7nAChR to enhance cognitive performance (Callahan et al., 2013). α7 PAMs increase the 
potency of both acetylcholine and direct agonists, enabling the effective dose to be lowered when 
these drugs are used together. Lowering the effective dose increases the therapeutic index (also 
referred to as therapeutic window), making drugs safer while reducing side effect profiles 
(Williams et al., 2011b). Additionally, while the orthosteric binding side is highly conserved 
throughout evolution, the allosteric site is less conserved, and therefore, has greater variability in 
the binding domain between receptor subtypes (Yang et al., 2012). This variation allows for 
highly selective PAMs. Orthosteric agonists can be less selective to an individual receptor, 
however, when used in conjunction with a PAM, can effectively become more selective. PAMs 
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will enhance the orthosteric activity at the target receptor, allowing for a reduced dose of agonist 
required to be effective. Because PAMs generally do not have affinity to other receptors, 
orthosteric activity at the non-target receptors is not enhanced and the reduced dose of agonist 
results in a decreased activity at these non-target receptors (Uteshev, 2014b). In other words, as a 
result of positive allosteric modulation of the target receptor, a lower dose of an orthosteric 
agonist can be used, reducing activity at receptors with similar orthosteric binding sites. Thus, 
PAMs may be used to reduce the side effects of orthosteric agonists and have benefits in 
treatment whether alone, or as a supplement to more direct therapeutics. 
α7nAChR PAMs have been demonstrated preclinically to improve performance in a 
variety of tasks, either alone or in conjunction with other orthosteric agonists. Two classes of α7 
PAMs were demonstrated in this study to significantly potentiate glutamate release during low 
levels of stimulation. During high levels of mesolimbic stimulation, the two classes had 
differential effects: the type I PAM produced either a potentiation or an attenuation of glutamate 
release at the low- and high-dose of PAM, respectively, whereas the type II PAM did not have an 
effect at either dose of PAM. The potentiation profiles of both types of PAM demonstrate the 
importance of the interaction between the dose of PAM and the level of stimulation as either 
PAM has varying effects depending on these interactions. Collectively, these results demonstrate 
the ability of α7nAChR PAMs to potentiate glutamate release in vivo and therefore, support 
further investigation into the use of α7nAChR PAMs in the treatment of cognitive deficits 
associated with schizophrenia.
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Figures 
 
Figure 1: enzyme detection scheme and photomicrograph of recording channels on MEA. Glutamate is oxidized by 
GluOx on glutamate-sensitive channels producing H2O2 and α-ketoglutarate. H2O2 is then reduced, generating a 
measurable current. Glutamate is not oxidized on sentinel channels. mPD on all channels prevents dopamine and 
ascorbic acid from generating a signal. Using this exclusion barrier and self-reference technique, glutamate can be 
measured selectively with sub-second resolution. 
 
Figure 2: a representative in vitro calibration of the MEA immediately prior to implantation. Glutamate-sensitive 
channels are represented by the black upper tracing whereas sentinel channels are below in blue. Time is represented 
on the x-axis (in seconds) and current is represented on the y-axis (in nA). Three additions of glutamate produce 
three equal increases in current. The slope of these additions is used to relate current and concentration of glutamate 
(nA/µM Glu). No change in current is detected on the sentinel channel after glutamate additions. Additionally, no 
response is observed after the addition of ascorbic acid or DA on either channel. Lastly, an addition of H2O2 is 
observed equally on all channels indicated equal sensitivity of all channels to the reporting molecule.
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Figure 3: coronal illustrations and sample placement of MEA and cannula. (A) Illustration of MEA between 
infralimbic and prelimbic corticies within the mPFC. (B) Photomicrograph of MEA placement indicated with arrow. 
(C) Illustration of cannula placement into the anterior shell of the NAc (NAcSH). (D) Photomicrograph of cannula 
placement into NAcSH. The upper arrow indicates the end of the steel guide cannula whereas the lower arrow 
indicates the location of the tip of the infusion cannula. 
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Figure 4: sample tracing from a single animal receiving low-dose of NMDA stimulation after both vehicle and low-
dose AVL-3288. The top tracing (red) is from a glutamate-sensitive channel (GluOx) and the middle tracing (blue) 
is from a sentinel channel. The bottom tracing is the self-referenced tracing obtained by subtracting the sentinel 
channel from the GluOx channel. In this representative example, the response of 0.05µg NMDA during vehicle 
treatment was potentiated in the presence of 1 mg/kg AVL-3288 from 2.83µM to 3.46µM glutamate, a percent 
change of 22%. 
 
 
Figure 5: sample self-referenced tracing from a single animal receiving high-dose of NMDA stimulation after both 
vehicle and high-dose AVL-3288. 3 mg/kg AVL-3288 attenuated glutamate release from 9.44µM to 7.16µM 
glutamate, a percent change of -24%. 
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Figure 6: AVL-3288 interacts with mesolimbic stimulation in evoked glutamate release. AVL-3288 data is 
presented as the percent change from NMDA-evoked glutamate after vehicle treatment. Absolute increases of 
glutamate during NMDA stimulation is reported in the inset graph. 1 mg/kg AVL-3288 significantly potentiated 
0.05µg NMDA-evoked glutamate release. When pretreated with 3 mg/kg AVL-3288, 0.05µg NMDA-evoked 
glutamate release was potentiated whereas 0.30µg NMDA-evoked glutamate release was attenuated. 
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Figure 7: sample self-referenced tracing from a single animal receiving low-dose of NMDA stimulation after both 
vehicle and high-dose PNU-120596. 9 mg/kg AVL-3288 potentiated glutamate release from 1.72µM to 4.27µM 
glutamate, a percent change of 148%. 
 
 
Figure 8: PNU-120596 interacts with mesolimbic stimulation in evoked glutamate release. PNU-120596 data is 
presented as the percent change from NMDA-evoked glutamate after vehicle treatment. Absolute increases of 
glutamate during NMDA stimulation is reported in the inset graph. 9 mg/kg AVL-3288 significantly potentiated 
0.05µg NMDA-evoked glutamate release. Glutamate release was not significantly potentiated or attenuated after 
0.30µg NMDA stimulation at either dose of PNU-120596. 
